Susanna A Mccolley

List of Publications by Year
in descending order

122	9,427	66343	38395
papers	citations	42	95
		h-index	g-index

124	124	124	7566
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections. Pediatric Pulmonology, 2023, 58, 672-682.	2.0	0
2	Cystic fibrosis year in review 2019: Section 3 multisystemâ€based care and research. Pediatric Pulmonology, 2023, 58, 697-703.	2.0	0
3	A rare case of pancytopenia in a child with cystic fibrosis: Can copper cure it all?. Pediatric Pulmonology, 2022, 57, 317-319.	2.0	1
4	Cystic Fibrosisâ€”Diagnosis, Genetics and Lifelong Effects. , 2022, , 146-160.		0
5	Genetic counseling access for parents of newborns who screen positive for cystic fibrosis: Consensus guidelines. Pediatric Pulmonology, 2022, 57, 894-902.	2.0	6
6	Editor's response to â€œAn oversight regarding the club cell?â€• Pediatric Pulmonology, 2022, 57, 2263-2263.	2.0	0
7	Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States. International Journal of Neonatal Screening, 2022, 8, 38.	3.2	7
8	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1239-1247.	5.6	13
9	Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Journal of Cystic Fibrosis, 2021, 20, 810-819.	0.7	62
10	Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. Pediatric Pulmonology, 2021, 56, 921-927.	2.0	2
11	Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatric Pulmonology, 2021, 56, 1496-1503.	2.0	81
12	Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. Science Translational Medicine, 2021, 13, .	12.4	65
13	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	5.6	146
14	Comment on Munck etÂal., Feb, 2021. Journal of Cystic Fibrosis, 2021, 20, 717-718.	0.7	2
15	Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation. Pediatric Blood and Cancer, 2021, 68, e29276.	1.5	0
16	Long-term safety of lumacaftorâ€“ivacaftor in children aged 2â€“5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 977-988.	10.7	28
17	Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. Pediatric Pulmonology, 2021, 56, 3758-3767.	2.0	15
18	Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 847-849.	0.7	0

#	Article	IF	Citations
19	Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients. Pediatric, Allergy, Immunology, and Pulmonology, 2020, 33, 63-68.	0.8	0
20	Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 3053-3056.	2.0	7
21	Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatric Pulmonology, 2020, 55, 3236-3242.	2.0	10
22	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
23	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. Journal of Cystic Fibrosis, 2019, 18, 94-101.	0.7	36
24	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	10.7	89
25	Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis. Scientific Reports, 2019, 9, 15483.	3.3	26
26	Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2â€“5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respiratory Medicine,the, 2019, 7, 325-335.	10.7	102
27	Cystic fibrosis year in review 2018, part 2. Pediatric Pulmonology, 2019, 54, 1129-1140.	2.0	7
28	Cystic fibrosis year in review 2018, part 1. Pediatric Pulmonology, 2019, 54, 1117-1128.	2.0	12
29	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
30	Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition. Journal of Cystic Fibrosis, 2019, 18, 778-780.	0.7	36
31	Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. Genes, 2019, 10, 180.	2.4	14
32	Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. Journal of Pediatric Surgery, 2019, 54, 1076-1082.	1.6	12
33	The demographics of adverse outcomes in cystic fibrosis. Pediatric Pulmonology, 2019, 54, S74-S83.	2.0	19
34	Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. Physiological Genomics, 2019, 51, 27-41.	2.3	14
35	Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review. International Journal of Eating Disorders, 2018, 51, 187-213.	4.0	51
36	The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. Journal of Cystic Fibrosis, 2018, 17, 34-42.	0.7	16

#	Article	IF	Citations
37	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Journal of Clinical and Translational Science, 2018, 2, 334-342.	0.6	28
38	Cystic fibrosis year in review 2017. Pediatric Pulmonology, 2018, 53, 1307-1317.	2.0	3
39	Designing trials for new cystic fibrosis modulators. Lancet Respiratory Medicine,the, 2018, 6, 484-486.	10.7	1
40	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	10.7	205
41	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. Journal of Pediatrics, 2017, 181, S4-S15.e1.	1.8	572
42	Aminoglycoside resistance ofPseudomonas aeruginosain cystic fibrosis results from convergent evolution in themexZgene. Thorax, 2017, 72, 40-47.	5.6	49
43	Diagnosis of Cystic Fibrosis in Screened Populations. Journal of Pediatrics, 2017, 181, S33-S44.e2.	1.8	82
44	Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology, 2017, 52, 909-915.	2.0	71
45	Cystic fibrosis year in review 2016. Pediatric Pulmonology, 2017, 52, 1092-1102.	2.0	9
46	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
47	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1144-1151.	5.6	96
48	The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opinion on Drug Safety, 2017, 16, 1305-1311.	2.4	34
49	Airway microbiota across age and disease spectrum in cystic fibrosis. European Respiratory Journal, 2017, 50, 1700832.	6.7	193
50	Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. BMC Pulmonary Medicine, 2017, 17, 160.	2.0	5
51	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508delâ€CFTR. Annals of the American Thoracic Society, 2017, 14, 213-219.	3.2	78
52	Pediatric Pulmonologyyear in review 2015: Part 4. Pediatric Pulmonology, 2016, 51, 754-765.	2.0	0
53	Minorities are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Annals of the American Thoracic Society, 2016, 13, 1721-1725.	3.2	44
54	Refining the continuum of <scp>CFTR</scp>â€associated disorders in the era of newborn screening. Clinical Genetics, 2016, 89, 539-549.	2.0	34

#	Article	IF	Citations
55	New insights into disease progression for the CFTR modulator-treated cystic fibrosis patient. Journal of Cystic Fibrosis, 2016, 15, e21.	0.7	0
56	A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opinion on Drug Safety, 2016, 15, 709-715.	2.4	19
57	Combination lumacaftor and ivacaftor therapy for cystic fibrosis. Expert Opinion on Orphan Drugs, 2016, 4, 233-242.	0.8	2
58	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	1.8	44
59	Sorting out the gray zone: Cystic fibrosis newborn screening. Journal of Cystic Fibrosis, 2015, 14, 681-682.	0.7	1
60	2014 year in review: Cystic fibrosis. Pediatric Pulmonology, 2015, 50, 1147-1156.	2.0	2
61	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
62	Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center. Pediatric, Allergy, Immunology, and Pulmonology, 2015, 28, 55-59.	0.8	5
63	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	10.7	197
64	Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening. Pediatrics, 2015, 135, e1386-e1392.	2.1	78
65	Practice Guidelines, Clinical Trials, and Unexpected Results in Cystic Fibrosis. Annals of the American Thoracic Society, 2014, 11, 402-403.	3.2	1
66	Primary Snoring. , 2014, , 209-214.		0
67	Ivacaftor therapy for cystic fibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 1225-1232.	0.8	3
68	Scholarship During Fellowship: Flexibility Unrealized. Pediatrics, 2014, 133, S80-S81.	2.1	0
69	Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives. BMJ Quality and Safety, 2014, 23, i81-i89.	3.7	13
70	Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. BMJ Quality and Safety, 2014, 23, i73-i80.	3.7	15
71	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	10.7	372
72	Pancreatic Enzyme Replacement Therapy Dosing and Nutritional Outcomes in Children with Cystic Fibrosis. Journal of Pediatrics, 2014, 164, 1110-1115.e1.	1.8	36

#	Article	IF	Citations
73	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	10.7	301
74	Trichosporon mycotoxinivorans Infection in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2014, 52, 2242-2244.	3.9	24
75	Update in Pediatric Lung Disease 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 293-297.	5.6	3
76	Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway Infection. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 171-178.	5.6	106
77	Update in Cystic Fibrosis 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 933-936.	5.6	9
78	Hispanic Infants with Cystic Fibrosis Show Low CFTR Mutation Detection Rates in the Illinois Newborn Screening Program. Journal of Genetic Counseling, 2012, 21, 671-675.	1.6	26
79	Update in Pediatric Lung Disease 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 30-34.	5.6	1
80	Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 135-143.	2.0	99
81	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 966-972.	2.0	15
82	Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis. Clinical Microbiology Reviews, 2011, 24, 29-70.	13.6	341
83	The Role Of Mexxy Efflux Pump Expression In The Development Of Aminoglycoside Resistance In P. Aeruginosa Over Time In Patients With Cystic Fibrosis. , 2011, , .		0
84	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	1.8	36
85	Longitudinal assessment of healthâ€related quality of life in an observational cohort of patients with cystic fibrosis. Pediatric Pulmonology, 2011, 46, 36-44.	2.0	85
86	Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients. Pediatric Pulmonology, 2011, 46, 683-687.	2.0	14
87	Parental Understanding of Newborn Screening for Cystic Fibrosis After a Negative Sweat-Test. Pediatrics, 2011, 127, 276-283.	2.1	31
88	The Need for Quality Improvement in Sweat Testing Infants after Newborn Screening for Cystic Fibrosis. Journal of Pediatrics, 2010, 157, 1035-1037.	1.8	38
89	Pediatric respiratory medicineâ€”an international perspective. Pediatric Pulmonology, 2010, 45, 14-24.	2.0	7
90	Utility Of Estimated Glomerular Filtration Rate Calculation In The Evaluation Of Nephrotoxicity Of Aminoglycisides In Cystic Fibrosis Patients. , 2010, , .		0

#	Article	IF	Citations
91	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 298-306.	5.6	225
92	This Issue: Pulmonology. Pediatric Annals, 2010, 39, 742-744.	0.8	0
93	Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, 634-639.e4.	1.8	92
94	Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatric Pulmonology, 2009, 44, 594-601.	2.0	40
95	EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. Journal of Cystic Fibrosis, 2009, 8, 405-417.	0.7	57
96	Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. Translational Research, 2008, 152, 257-264.	5.0	43
97	Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function. Pediatrics, 2007, 119, e531-e537.	2.1	60
98	A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respiratory Care, 2007, 52, 258-62.	1.6	25
99	HETEROGENEITY IN ANTIBIOTIC SUSCEPTIBILITIES OF PSEUDOMONAS AERUGINOSA RESPIRATORY ISOLATES FROM INDIVIDUALS WITH CYSTIC FIBROSIS. Chest, 2006, 130, 138S.	0.8	1
100	ATS Consensus Statement. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 776-780.	5.6	13
101	Primary Snoring in Children. , 2005, , 263-267.		2
102	Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis. Journal of Clinical Microbiology, 2004, 42, 5229-5237.	3.9	177
103	Cystic fibrosis lung disease: When does it start, and how can it be prevented?. Journal of Pediatrics, 2004, 145, 6-7.	1.8	7
104	Treatment of Plastic Bronchitis in a Fontan Patient With Tissue Plasminogen Activator: A Case Report and Review of the Literature. Pediatrics, 2002, 109, e67-e67.	2.1	91
105	Clinical Practice Guideline: Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. Pediatrics, 2002, 109, 704-712.	2.1	883
106	Postexercise immune correlates in children with and without cystic fibrosis. Medicine and Science in Sports and Exercise, 2000, 32, 1997-2004.	0.4	5
107	Serum Vascular Endothelial Growth Factor Is Elevated in Cystic Fibrosis and Decreases with Treatment of Acute Pulmonary Exacerbation. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1877-1880.	5.6	80
108	Immune Modulation Following Aerobic Exercise in Children with Cystic Fibrosis. International Journal of Sports Medicine, 2000, 21, 294-301.	1.7	14

#	Article	IF	Citations
109	Parental Attitudes About Exercise Regarding Their Children with Cystic Fibrosis. International Journal of Sports Medicine, 1999, 20, 334-338.	1.7	10
110	Energy metabolism during anaerobic exercise in children with cystic fibrosis and asthma. Medicine and Science in Sports and Exercise, 1999, 31, 1242-1249.	0.4	21
111	BRONCHOPULMONARY DYSPLASIA. Pediatric Clinics of North America, 1998, 45, 573-586.	1.8	11
112	Wheezing or Stridor: Intrinsic and Extrinsic Lesions Causing Noisy Breathing. Allergy and Asthma Proceedings, 1998, 19, 81-84.	2.2	2
113	High Prevalence of Allergic Sensitization in Children With Habitual Snoring and Obstructive Sleep Apnea. Chest, 1997, 111, 170-173.	0.8	192
114	Polysomnography in the Evaluation of Readiness for Decannulation in Children. JAMA Otolaryngology, 1996, 122, 721-724.	1.2	44
115	Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea. Critical Care Medicine, 1996, 24, 1323-1327.	0.9	81
116	Inability of Clinical History to Distinguish Primary Snoring From Obstructive Sleep Apnea Syndrome in Children. Chest, 1995, 108, 610-618.	0.8	591
117	Immune response to influenza vaccination in children with renal disease. Pediatric Nephrology, 1995, 9, 566-568.	1.7	52
118	Upper airway collapsibility in children with obstructive sleep apnea syndrome. Journal of Applied Physiology, 1994, 77, 918-924.	2.5	228
119	Polysomnographic characteristics of patients with Rett syndrome. Journal of Pediatrics, 1994, 125, 218-224.	1.8	82
120	Respiratory Compromise After Adenotonsillectomy in Children With Obstructive Sleep Apnea. JAMA Otolaryngology, 1992, 118, 940-943.	1.2	335
121	Effect of oxygenation on breath-by-breath response of the genioglossus muscle during occlusion. Journal of Applied Physiology, 1991, 71, 1231-1236.	2.5	15
122	Differences in Expression of Cystic Fibrosis in Blacks and Whites. JAMA Pediatrics, 1991, 145, 94.	3.0	10